Literature DB >> 12398907

5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy.

Eric P M Prinssen1, Francis C Colpaert, Wouter Koek.   

Abstract

Studies have shown that 5-HT1A receptor ligands modulate antipsychotic-induced catalepsy. Here, we further examined the role of intrinsic activity at 5-HT1A receptors in these effects. The anti-cataleptic effects of 5-HT(1A) receptor ligands with positive intrinsic activity [from high to low: 3-chloro-4-fluorophenyl-(4-fluoro-4-[[(5-methyl-6-methylamino-pyridin-2-ylmethyl)-amino]-methyl]-piperidin-1-yl-methanone fumaric acid salt (F 13714), eptapirone, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), 2-[4-[4-(7-methoxy-1-naphtyl) piperazino]butyl]-4-methyl-2H,4H-1,2,4-triazin-3,5-dione maleic acid salt (F 11461), buspirone, 2-[4-[4-(7-benzofuranyl)piperazino]butyl]-4-methyl-2H,4H-1,2,4-triazin-3,5-dione (F 12826), ipsapirone, and (s)-N-tert-butyl-3-(4-(2-methoxyphenyl)piperazine-1-yl)-2-phenylpropanamide hydrochloride (WAY 100135)] and negative intrinsic activity [N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide dihydrochloride (WAY 100635)] were examined. Catalepsy was induced by the classical antipsychotic haloperidol (0.63 mg/kg) and measured in the cross-legged position test and in the bar test. All 5-HT1A receptor agonists, except WAY 100135, significantly attenuated the effects of haloperidol in the cross-legged position test. All agonists had similar effects in the bar test, except ipsapirone, which failed to attenuate haloperidol-induced catalepsy. In contrast to the effects observed with the agonists, the inverse agonist WAY 100635 appeared to enhance haloperidol-induced catalepsy in both tests, in agreement with earlier findings. The maximal effects of the 5-HT1A receptor ligands to attenuate catalepsy correlated positively with the rank order of their intrinsic activity at 5-HT1A receptors (either catalepsy test: r(S)=0.92, P<0.001). F 13714, which had the highest intrinsic activity, maximally inhibited haloperidol-induced catalepsy in the cross-legged position and bar tests (100% and 99% inhibition, respectively). Because the magnitude of the anti-cataleptic effects of 5-HT1A receptor ligands correlates positively with their intrinsic activity, it is likely that F 13714 has marked anti-cataleptic effects because of its high intrinsic activity at 5-HT1A receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12398907     DOI: 10.1016/s0014-2999(02)02430-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  24 in total

Review 1.  Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Authors:  Yukihiro Ohno
Journal:  CNS Neurosci Ther       Date:  2010-11-21       Impact factor: 5.243

Review 2.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

3.  Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.

Authors:  Isabelle Rauly-Lestienne; Elisa Boutet-Robinet; Marie-Christine Ailhaud; Adrian Newman-Tancredi; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-05       Impact factor: 3.000

4.  Clozapine-induced locomotor suppression is mediated by 5-HT2A receptors in the forebrain.

Authors:  Caitlin E McOmish; Alena Lira; James B Hanks; Jay A Gingrich
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

5.  Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument.

Authors:  Barbara Bricker; Dinithia Sampson; Seth Y Ablordeppey
Journal:  Pharmacol Biochem Behav       Date:  2014-02-21       Impact factor: 3.533

6.  Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.

Authors:  Saki Shimizu; Yukihiro Ohno
Journal:  Aging Dis       Date:  2012-11-29       Impact factor: 6.745

7.  Role of vasopressin V1a receptor in ∆9-tetrahydrocannabinol-induced cataleptic immobilization in mice.

Authors:  Nobuaki Egashira; Emi Koushi; Takayuki Myose; Akito Tanoue; Kenichi Mishima; Ryota Tsuchihashi; Junei Kinjo; Hiroyuki Tanaka; Satoshi Morimoto; Katsunori Iwasaki
Journal:  Psychopharmacology (Berl)       Date:  2017-09-14       Impact factor: 4.530

8.  Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation.

Authors:  Mark S Kleven; Marie-Bernadette Assié; Cristina Cosi; Catherine Barret-Grévoz; Adrian Newman-Tancredi
Journal:  Psychopharmacology (Berl)       Date:  2004-09-24       Impact factor: 4.530

9.  Effects of chronic buspirone treatment on cocaine self-administration.

Authors:  Nancy K Mello; Peter A Fivel; Stephen J Kohut; Jack Bergman
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

10.  The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?

Authors:  J Srinivasan; Werner J Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-29       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.